Related Experiment Videos
Usefulness of K-1 (CD-30) marker in Hodgkin's disease
K A Shakoor1, A Saleh, M S Khanzada
1Department of Pathology, BMSI, Jinnah Postgraduate Medical Centre, Karachi.
Insights
The Ki-1 (CD-30) immunomarker reliably identifies Hodgkin
Area of Science:
- Hematopathology
- Immunohistochemistry
- Oncology
Background:
- Hodgkin's disease diagnosis relies on identifying specific cells, often challenging on standard H&E stains.
- Reed-Sternberg cells, characteristic of Hodgkin's disease, can be morphologically similar to cells in other lymphoproliferative disorders.
- A single, specific immunomarker could improve diagnostic accuracy and differentiate Hodgkin's disease from other conditions.
Purpose of the Study:
- To evaluate the diagnostic utility of the Ki-1 (CD-30) immunomarker for identifying Hodgkin's and Reed-Sternberg-like cells.
- To determine the specificity of Ki-1 (CD-30) in distinguishing Hodgkin's disease from other lymphoproliferative lesions.
- To assess the reliability of Ki-1 (CD-30) as a single marker for Hodgkin's disease diagnosis.
Main Methods:
- Seventy-nine lymph node biopsies were analyzed, including 59 Hodgkin's disease, 15 Non-Hodgkin's lymphoma, and 5 non-neoplastic cases.
- All cases exhibited Hodgkin's or Reed-Sternberg-like cells on H&E staining.
- Ki-1 (CD-30) immunostaining was performed on all biopsy samples.
Main Results:
- 83% (49/59) of Hodgkin's disease cases showed positive Ki-1 (CD-30) immunoreactivity.
- None of the 15 Non-Hodgkin's lymphoma cases tested positive for Ki-1 (CD-30).
- Only one of the 5 non-neoplastic lymphoid lesions exhibited positive Ki-1 (CD-30) staining.
Conclusions:
- Ki-1 (CD-30) is a dependable marker for identifying Hodgkin's and Reed-Sternberg-like cells in confirmed Hodgkin's disease.
- The marker demonstrates high specificity, differentiating Hodgkin's disease from other lymphoproliferative conditions.
- Ki-1 (CD-30) immunostaining is a valuable tool for accurate Hodgkin's disease diagnosis.
Objective:
To identify Hodgkin's and Reed Sternberg like cells by a single Immunomarker (Ki-1; CD-30) and to highlight diagnostic specificity of these cells in Hodgkin's disease, as these cells are frequently encountered in other lymphoproliferative disorders on H&E sections.
Methodology:
Seventy-nine histologically diagnosed cases of lymph node biopsies (59 cases of Hodgkin's disease, 15 cases of Non Hodgkin's lymphoma and 5 cases of non neoplastic lymphoid tissue) were subjected to Ki-1 (CD-30) immunostaining as all cases revealed Hodgkin's and/or Reed Sternberg like cells on H&E stained sections.
Results:
Out of 59 cases of Hodgkin's disease, 49 (83%) showed Ki-1 (CD-30) immunoreactivity for Reed Sternberg and Hodgkin's cells. None of the 15 cases of non-Hodgkin's lymphoma (2 small lymphocyte type, 11 diffuse large cells type, 2 lymphoblastic type) showed positive Ki-1 (CD-30) immunostaining. Only one case of the remaining 5 cases of non-neoplastic lymphoid lesion (2 toxoplasmic lymphadenitis, one histiocytic necrotizing lymphadenitis, one reactive hyperplasia and one chronic non specific lymphadenitis) showed positive Ki-1 immunostaining.
Conclusion:
Ki-1 (CD-30) is a reliable marker for Hodgkin's Reed Sternberg like cells in histologically proven cases of Hodgkin's disease but not for similar cells encountered in other lymhoproliferative lesions.